Jump to content

Sinovac Biotech

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Bender the Bot (talk | contribs) at 05:55, 12 November 2016 (→‎top: clean up; http→https for Google Books and other Google services using AWB). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Sinovac Biotech Ltd. (Chinese: 北京科兴生物制品有限公司) is a biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. The company is based in Beijing, China.

Sinovac's commercialized vaccines include Healive (hepatitis A), Bilive (combined hepatitis A and B), Anflu (influenza), Panflu (H5N1) and PANFLU.1 (H1N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine.[1]

Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

References